THE BIOTECH TRADER HANDBOOK

Pages

Sunday, October 9, 2011

I want to thank you for visiting biotechtraderhandbook.com over the past few years. It has been my pleasure to provide what I hope has been insightful trading strategies for the biotech and pharmaceutical sectors.

I am proud to announce that Jason Chew, Patrick Crutcher, Tro Khalijian, Richard Kursman and I have co-founded Chimera Research Group, where I will be serving as Trade Strategist. On Tuesday, October 11th, the site will officially launch.

Chimera Research Group will provide completely independent, actionable investment and trading ideas backed by comprehensive research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage will focus on early stage companies with impending FDA decisions or clinical trial results, in addition to mid-to-large cap bio-pharma companies with known catalysts.

I appreciate your patronage and I hope you will continue to follow my work at Chimera Research Group, where my co-founders and I will provide the best content available in the bio-pharmaceutical sectors. Please visit www.ChimeraResearchGroup.com for more information.

Wednesday, March 30, 2011

XenoPort Inc. (XNPT) is set to receive notification from the FDA on April 6 whether or not their restless leg syndrome drug Horizant is approved. I intend to trade this event using both a bullish and bearish approach – as of writing, however, I have only managed to execute the bullish side of the trade...

Monday, March 14, 2011

The updated 2nd Edition of the Biotech Trader Handbook includes over 70 pages of new, value-added content on top of the existing content. This includes the following:

• Chapter 2.0, Trade Candidate Identification: This chapter was expanded to include recent developments in on-line resources and social media such as the use of Twitter, value-added blogs and full coverage websites.

• Chapter 4.0, Option Basics: This chapter was added to benefit readers without any prior knowledge of options. The chapter seeks to introduce the subject conceptually and from a trading perspective (i.e. practical, real life) and provides an initial basis to understand the more complex trade structures described later in the book.

• Chapter 6.0, Trade Structures: This chapter includes four new (and innovative) trading structures on top of the existing eleven structures included in the prior version.

• Chapter 7.0, Trade Process: This chapter was added to provide the reader a simple process to identify low risk / high reward trades where there is no initial bullish, bearish or neutral trade conviction. Several trade examples are included.

Tuesday, March 8, 2011

Human Genome Sciences (HGSI) is slated to receive a response from the FDA by Thursday, March 10, on whether or not its drug Benlysta is approved. I am trading this catalyst event using a Call butterfly spread with an overlaid tight long Call spread...To read the entire article, please click here.

Subscribe

Tony Pelz - Seeking Alpha

About Me

Tony Pelz was a trader on a major European bank's proprietary trading desk. He was responsible for a portfolio with limits of more than $200 million.
Prior to proprietary trading, Mr. Pelz worked with several major global investment banks in roles ranging from corporate finance, mergers and acquisitions to credit and business development. He has substantial international work experience in Asia, U.S., Europe and Latin America and was based in New York City, Bogotá (Colombia), Rio de Janeiro (Brazil) and Amsterdam (The Netherlands). Mr. Pelz currently trades for his own account.
Mr. Pelz is also the author of The Biotech Trader Handbook.